BHT ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 6 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-001340-22-CZ (EUCTR) | 09/04/2006 | 30/08/2005 | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP). | Product Name: BHT-3009 Product Code: BHT-3009 | Bayhill Therapeutics | NULL | Not Recruiting | Female: yes Male: yes | 252 | Finland;United Kingdom;Czech Republic | |||
| 2 | NCT00382629 (ClinicalTrials.gov) | February 2006 | 27/9/2006 | BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis | BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Drug: BHT-3009 0.5 mg;Drug: BHT-3009 1.5 mg;Drug: Placebo | Bayhill Therapeutics | NULL | Completed | 18 Years | 55 Years | Both | 252 | Phase 2 | NULL |
| 3 | EUCTR2005-001340-22-FI (EUCTR) | 29/11/2005 | 22/07/2005 | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP). | Product Name: BHT-3009 Product Code: BHT-3009 | Bayhill Therapeutics | NULL | Not Recruiting | Female: yes Male: yes | 252 | Finland;Czech Republic;United Kingdom | |||
| 4 | EUCTR2005-001340-22-SK (EUCTR) | 27/09/2005 | 29/07/2005 | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP). | Product Name: BHT-3009 Product Code: BHT-3009 | Bayhill Therapeutics | NULL | Not Recruiting | Female: yes Male: yes | 252 | Phase 2 | Czech Republic;Slovakia;Finland;United Kingdom | ||
| 5 | EUCTR2005-001340-22-GB (EUCTR) | 12/08/2005 | 18/07/2005 | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP). | Product Name: BHT-3009 Product Code: BHT-3009 | Bayhill Therapeutics | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 252 | Finland;Czech Republic;United Kingdom | |||
| 6 | NCT00103974 (ClinicalTrials.gov) | July 2004 | 17/2/2005 | Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis | A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis | Multiple Sclerosis | Biological: BHT-3009-01 | Bayhill Therapeutics | NULL | Completed | 18 Years | 65 Years | Both | 30 | Phase 1 | United States;Canada |